Impairment of upper airway patency and CPAP effectiveness during obstructive sleep apnea treatment with expiratory pressure alleviation: a randomized study
- Journal
- Chest (Q1)
- Published
- 3 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Gustavo Freitas Grad, Ivana Rosanelli, Mariana Delgado Fernandes, Aline Brunacci Monare, Marcela Yanagimori, Iris Fragoso da Silva Cruz, et al.
- PMID
- 42692288
- DOI
- 10.1016/j.chest.2026.08.041
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (top studies of the week, 25 October 2026): Expiratory pressure alleviation impairs CPAP effectiveness in OSA
Abstract
BACKGROUND: Expiratory pressure alleviation (EPA) algorithms have been incorporated into CPAP devices to reduce expiratory discomfort during treatment of obstructive sleep apnea (OSA). Since pharyngeal narrowing or collapse can occur during expiration, EPA may impair upper airway patency. RESEARCH QUESTION: Does EPA compromise upper airway patency and CPAP efficacy in patients with severe OSA? STUDY DESIGN AND METHODS: Adults with severe OSA using nasal CPAP were considered to participate. The study was conducted in four steps. Steps 1 and 2 were performed during a single overnight polysomnography (PSG) study. In step 1, peak inspiratory flow (PIF) was measured during inspiratory flow limitation with and without EPA. In step 2, CPAP titration was performed in randomized order with and without EPA. Steps 3 and 4 were conducted at home. Residual AHI and adherence were compared with and without EPA activation during fixed (Step 3) and auto-CPAP (Step 4). RESULTS: Twenty-nine subjects were studied (55% female; age 63±12 years; BMI 37±7 kg/m2; AHI 58 (39-83) events/h). EPA activation reduced PIF compared to without EPA (0.38 (0.34-0.42) vs 0.19 (0.15-0.23) L/s), respectively (P<0.001). Manually titrated CPAP level was higher with EPA than without EPA (11.40 ± 1.95 vs 9.17 ± 1.78 cmH2O), respectively (P<0.001). Residual AHI was higher with EPA than without EPA, during fixed (3.7 ± 2.2 vs 1.3 ± 0.6 events/h) and automatic CPAP (1.4 (0.6 - 2.1) vs (0.8 (0.5-1.8) events/h), respectively (P<0.05). No significant change in CPAP adherence was observed, during fixed (7.0 ± 0.8 vs 7.2 ± 1.0 hours) and automatic CPAP (7.0 ± 1.3 vs 6.9 ± 1.3 hours), with (P=0.497) and without (P=0.506) EPA, respectively. INTERPRETATION: EPA application compromised upper airway patency and required higher therapeutic CPAP than without EPA. EPA also impaired OSA control but did not impact CPAP adherence. CLINICAL TRIALS REGISTRY: NCT05219591.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.